SCHEMBL4336208

SCHEMBL4336208

NC1(C(=O)O)C=CC=C(c2ccccc2O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
HPGD P15428 4/20 0.34
HSD17B10 Q99714 2/20 0.34
BCL2L1 Q07817 1/20 0.34
HTR2B P41595 2/20 0.31
THRB P10828 3/20 0.31
TDP1 Q9NUW8 2/20 0.31
KDM4E B2RXH2 3/20 0.31
CYP2D6 P10635 1/20 0.31
RAB9A P51151 1/20 0.31
POLB P06746 2/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
TTR P02766 1/20 0.30
BCHE P06276 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28418518 0.83 POLB (0.33) ALDH1A1HPGDHSD17B10KDM4ECYP2D6
SCHEMBL29007685 0.81 HDAC4 (0.32) ALDH1A1HPGDTHRBTDP1RAB9A
SCHEMBL6846865 0.81 NPC1 (0.35) ALDH1A1HPGDHSD17B10KDM4EMEN1
SCHEMBL6851099 0.77 PTPN1 (0.31) ALDH1A1HPGDHSD17B10BCL2L1
SCHEMBL6850680 0.75 PTPN5 (0.31) ALDH1A1HPGDHSD17B10BCL2L1
SCHEMBL6852957 0.75 ALDH1A1 (0.31) ALDH1A1HPGDHSD17B10BCL2L1
SCHEMBL19379856 0.72 GRM4 (0.33)
SCHEMBL10872336 0.71 SRR (0.33) ALDH1A1HSD17B10TDP1KDM4ERAB9A
SCHEMBL7551777 0.71 ALDH1A1 (0.33) ALDH1A1HPGDHSD17B10THRBTDP1
SCHEMBL6852914 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115322110-B Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2024-03-19 CN claimed
CN-115322110-A Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2022-11-11 CN claimed
CN-114317127-A Fluoride-free cleaning agent, and preparation method and application thereof 嘉庚创新实验室 2022-04-12 CN claimed
CN-114230517-A Method for processing eltrombopag 杭州煌森生物科技有限公司 2022-03-25 CN claimed
CN-115322110-B Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2024-03-19 CN disclosed
CN-115322110-B Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2024-03-19 CN disclosed
CN-115322110-B Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2024-03-19 CN disclosed
CN-115322110-A Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2022-11-11 CN disclosed
CN-115322110-A Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2022-11-11 CN disclosed
CN-115322110-A Method for synthesizing eltrombopag intermediate 3 '-amino-2' -hydroxybiphenyl-3-carboxylic acid 常熟理工学院 2022-11-11 CN disclosed
CN-114317127-A Fluoride-free cleaning agent, and preparation method and application thereof 嘉庚创新实验室 2022-04-12 CN disclosed
CN-114230517-A Method for processing eltrombopag 杭州煌森生物科技有限公司 2022-03-25 CN disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALDH1A1 1012/4885HPGD 1200/4885HSD17B10 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.